The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026, inclusive (“the Class Period”). If you suffered a loss on your Anavex investments, you have until November 30, 2026 to request lead plaintiff appointment.
[CONTACT THE FIRM IF YOU SUFFERED A LOSS]
Investors are encouraged to fill out the contact form above or contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
What Is This Lawsuit About? The lawsuit alleges that Anavex made false and/or misleading statements and failed to disclose that: (i) Anavex lacked adequate internal controls; and (ii) Anavex understated its potential regulatory challenges as a result of misconduct by former CEO Christopher Missling.
On May 6, 2026, Anavex filed a report on Form 8-K with the SEC, disclosing that, on April 30, 2026, a special committee of Anavex Board of Directors “terminated the employment” of the Company’s Chief Executive Officer Christopher Missling. The report stated that the termination was “effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy.” On this news, the price of Anavex shares declined by $0.02, or approximately 0.59%, from $3.36 per share on May 5, 2026 to close at $3.34 on May 6, 2026.
Then, on May 11, 2026, Anavex filed with the SEC a notification of late filing on Form 12-25, which stated that the Company was unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 by the prescribed May 11, 2026 due date. The Company attributed this to the termination of CEO Missling, stating, “Until the Special Committee and the Company complete their review of certain matters related to the termination of Dr. Missling… the Company will be unable to complete its preparation and review of the Form 10-Q without unreasonable effort or expense.” On this news, the price of Anavex shares declined by $0.18 per share, or approximately 5.55%, from $3.24 per share on May 11, 2026 to close at $3.06 on May 12, 2026.
Finally, on August 28, 2026, Anavex filed with the SEC an amended Annual Report on Form 10-K/A for the fiscal year ended September 30, 2025. The report disclosed that “the Company’s disclosure controls and procedures were not effective as of September 30, 2025, due to the material weakness in internal control over financial reporting.” The Company also stated, “There was a lack of transparency with the board regarding regulatory, clinical and non-financial matters, and the former CEO failed to foster an environment which prioritized regulatory and clinical compliance and in fact took steps to disincentives such efforts.” On this news, the price of Anavex shares declined by $0.19 per share, or approximately 6.35%, from $2.99 per share on August 28, 2026 to close at $2.80 on August 31, 2026.
[LEARN MORE ABOUT THE LAWSUIT]
The Lead Plaintiff Appointment Process. The federal securities laws permit any investor who acquired eligible securities during the class period to seek appointment as lead plaintiff in a class action lawsuit. Courts do not consider lead plaintiff applications submitted after the relevant deadline. If you choose to take no action, you may remain an absent class member. Learn more about the lead plaintiff process and eligibility requirements here. Courts typically appoint the investor(s) with the largest financial loss in the case and the ability to represent the class rather than investors with simply the largest investment portfolio. Courts regularly appoint individual investors, whether acting alone or as a group, as lead plaintiffs. The rights of any investor who bought shares during the class period are generally already protected. However, lead plaintiffs have the power to influence case strategy and have a say in settlement decisions, as well as decisions concerning allocation of settlement funds among class members.
[LEARN MORE ABOUT THE LEAD PLAINTIFF PROCESS]
What Should I Do? If you purchased or otherwise acquired Anavex securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found on Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260930195666/en/
Media gallery
